Literature DB >> 11727369

Varus derotation osteotomy for the treatment of hip subluxation and dislocation in cerebral palsy: statistical analysis in 73 hips.

K J Noonan1, T L Walker, K J Kayes, J Feinberg.   

Abstract

The purpose of this study is to review the results of varus osteotomy in patients with cerebral palsy and to determine factors that influence the rates of residual hip displacement. A retrospective chart review of 65 patients who underwent 79 varus osteotomies was performed. Preoperative, postoperative and follow-up radiographs were analyzed for routine radiographic measurements, pelvic obliquity, osteonecrosis (avascular necrosis), joint incongruity or degenerative joint disease. The average follow-up was 5.2 years (range, 1.1-18.4 years). At follow-up, 3 hips were dislocated, 19 were subluxated and 57 were stable (72%). Age at surgery and the degree of preoperative hip displacement had significant effects on outcome. The average age at surgery for initially subluxated hips, which were located at follow-up, was 7.2 years. This was significantly younger (P = 0.008) than initially subluxated hips, which were displaced (10 years of age). Subluxated hips at surgery were also more likely to be located at follow-up than dislocated hips.

Entities:  

Mesh:

Year:  2001        PMID: 11727369

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  13 in total

1.  Early results of one-stage correction for hip instability in cerebral palsy.

Authors:  Hui Taek Kim; Jae Hoon Jang; Jae Min Ahn; Jong Seo Lee; Dong Joon Kang
Journal:  Clin Orthop Surg       Date:  2012-05-17

2.  Determinants of Hip Displacement in Children With Cerebral Palsy.

Authors:  Chia Hsieh Chang; Ying Chih Wang; Pei Chi Ho; Ai Wen Hwang; Hsuan Kai Kao; Wei Chun Lee; Wen E Yang; Ken N Kuo
Journal:  Clin Orthop Relat Res       Date:  2015-08-20       Impact factor: 4.176

3.  Risk factors and complications in hip reconstruction for nonambulatory patients with cerebral palsy.

Authors:  Joseph J Ruzbarsky; Nicholas A Beck; Keith D Baldwin; Wudbhav N Sankar; John M Flynn; David A Spiegel
Journal:  J Child Orthop       Date:  2013-10-15       Impact factor: 1.548

4.  Neurogenic hip dislocation in cerebral palsy: quality of life and results after hip reconstruction.

Authors:  Alexander Krebs; Walter M Strobl; Franz Grill
Journal:  J Child Orthop       Date:  2008-02-13       Impact factor: 1.548

5.  One-stage hip reconstruction in children with cerebral palsy: long-term results at skeletal maturity.

Authors:  Cindy Mallet; B Ilharreborde; A Presedo; A Khairouni; K Mazda; G F Penneçot
Journal:  J Child Orthop       Date:  2014-05-06       Impact factor: 1.548

6.  Avascular necrosis in children with cerebral palsy after reconstructive hip surgery.

Authors:  L Phillips; K Hesketh; E K Schaeffer; J Andrade; J Farr; K Mulpuri
Journal:  J Child Orthop       Date:  2017-10-01       Impact factor: 1.548

7.  Fate of stable hips after prophylactic femoral varization osteotomy in patients with cerebral palsy.

Authors:  Ki Hyuk Sung; Soon-Sun Kwon; Chin Youb Chung; Kyoung Min Lee; Jaeyoung Kim; Seung Yeol Lee; Moon Seok Park
Journal:  BMC Musculoskelet Disord       Date:  2018-04-27       Impact factor: 2.362

8.  The effect of hip reconstruction on gross motor function levels in children with cerebral palsy.

Authors:  Mutlu Cobanoglu; Emre Cullu; Imran Omurlu
Journal:  Acta Orthop Traumatol Turc       Date:  2017-11-23       Impact factor: 1.511

9.  Combined pelvic and femoral reconstruction in children with cerebral palsy.

Authors:  Nabil Alassaf; Neil Saran; Theirry Benaroch; Reggie Cherine Hamdy
Journal:  J Int Med Res       Date:  2017-08-21       Impact factor: 1.671

10.  Outcome of Femoral Varus Derotational Osteotomy for the Spastic Hip Displacement: Implication for the Indication of Concomitant Pelvic Osteotomy.

Authors:  Hoon Park; Sharkawy Wagih Abdel-Baki; Kun-Bo Park; Byoung Kyu Park; Isaac Rhee; Seung-Pyo Hong; Hyun Woo Kim
Journal:  J Clin Med       Date:  2020-01-17       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.